The ACHN patent application covers levels of deuterium enrichment at the claimed positions (5-prime of ribose and uridine) of 50-99% in various embodiments. Hence the point you brought up is not a concern if the patent is allowed ... which I expect it will be, based on the four separate benefits of deuteration that are shown in the examples.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.